Skip to Content

'
Elisabet E Manasanch, MD

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2014 Duke University, Durham, NC, MHSc, Master of Health Sciences in Clinical Research
2005 University of Barcelona, Barcelona, Spain, MD, Medicine

Postgraduate Training

7/2013-3/2014 Clinical Fellowship, Multiple Myeloma Section, NCI - National Institutes of Health, Bethesda, MD
7/2010-7/2013 Clinical Fellowship, Hematology-Oncology, National Institutes of Health - NCI/NHLBI, Bethesda, MD
7/2007-7/2010 Clinical Residency Internal Medicine, The University of Massachusetts Medical School, Worcester, MD
11/2005-5/2007 Postgraduate Studies in Cell Biology of Cancer, University of Barcelona, Barcelona, Spain

Board Certifications

2013 Medical Oncology, 2013
2010 Internal Medicine

Honors and Awards

2005 Agusti Pedro I Pons Foundation Grant for Postgraduate Studies, Agusti Pedro I Pons Foundation
2005 Honors in final clerkships: Pediatrics, Obstetrics/Gynecology, Psychiatry, Hematology and Neurology, University of Barcelona
2003 Catalan Society of Biology, Students' Award, Awarded by Jordi Pujol, president of Catalonia 1980-2003 (Spain)
2003 Erasmus-Socrates Europen Union Grant, Erasmus-Socrates Europen Union Program
2001 International Relations Office of the Univeristy of Barcelona Grant, University of Barcelona

Professional Memberships

American Society of Clinical Oncology
Member, 2010-present
American Society of Hematology
Associate Member, 2010-present
European Hematology Association
Junior Corresponding Member, 2012-present
International Myeloma Working Group
Member, 2013-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Zingone A, Wang W, Corrigan-Cummins M, Wu SP, Plyler R, Korde N, Kwok M, Manasanch EE, Tageja N, Bhutani M, Mulquin M, Zuchlinski D, Yancey MA, Roschewski M, Zhang Y, Roccaro AM, Ghobrial IM, Calvo KR, Landgren O. Altered cytokine and chemokine profiles in multiple myeloma and precursor disease. Cytokine. e-Pub 7/2014. PMID: 25043675.
2. Korde N, Carlsten M, Lee MJ, Minter A, Tan E, Kwok M, Manasanch E, Bhutani M, Tageja N, Roschewski M, Zingone A, Costello R, Mulquin M, Zuchlinski D, Maric I, Calvo KR, Braylan R, Tembhare P, Yuan C, Stetler-Stevenson M, Trepel J, Childs R, Landgren O. A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. Haematologica. e-Pub 3/2014. PMID: 24658821.
3. Tembhare PR, Yuan CM, Venzon D, Braylan R, Korde N, Manasanch E, Zuchlinsky D, Calvo K, Kurlander R, Bhutani M, Tageja N, Maric I, Mulquin M, Roschewski M, Kwok M, Liewehr D, Landgren O, Stetler-Stevenson M. Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases. Leuk Res 38(3):371-6, 3/2014. e-Pub 12/2013. PMCID: PMC3947595.
4. Tageja N, Manasanch EE., Korde N, Kwok M, Mailankody S, Bhutani M, Roschewski M, Landgren O. Smoldering multiple myeloma: present position and potential promises. Eur J Haematol 92(1):1-12, 1/2014. e-Pub 11/2013. PMID: 24112232.
5. Manasanch EE, Korde N, Zingone A, Tageja N, Fernandez de Larrea C, Bhutani M, Wu P, Roschewski M, Landgren O. The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myeloma. Leuk Lymphoma. e-Pub 1/2014. PMID: 24261677.
6. Cherry BM, Korde N, Kwok M, Manasanch EE, Bhutani M, Mulquin M, Zuchlinski D, Yancey MA, Maric I, Calvo KR, Braylan R, Stetler-Stevenson M, Yuan C, Tembhare P, Zingone A, Costello R, Roschewski MJ, Landgren O. Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study. Leuk Lymphoma 54(10):2215-8, 10/2013. e-Pub 7/2013. PMID: 23311294.
7. Manasanch EE, Kristinsson SY, Landgren O. Etiology of Waldenström macroglobulinemia: genetic factors and immune-related conditions. Clin Lymphoma Myeloma Leuk 13(2):194-7, 4/2013. e-Pub 3/2013. PMID: 23473950.
8. Cherry BM, Costello R, Zingone A, Burris J, Korde N, Manasanch E, Kwok M, Annunziata C, Roschewski MJ, Engels EA, Landgren O. Immunoparesis and monoclonal gammopathy of undetermined significance are disassociated in advanced age. Am J Hematol 88(2):89-92, 2/2013. e-Pub 11/2012. PMID: 23169485.
9. Manasanch EE, Grivas P, Walter O, Davaro R. Kidney actinomycosis, a rare diagnosis that can mimic renal cell carcinoma: a case report and review of the literature. Infectious Diseases in Clinical Practice 20(5):362-364, 2012.
10. Manasanch EE, Smith JK, Bodnari A, McKinney J, Gray C, McDade TP, Tseng JF. Tumor registry versus physician medical record review: a direct comparison of patients with pancreatic neuroendocrine tumors. J Oncol Pract 7(2):111-6, 3/2011. PMCID: PMC3051856.
11. Villano JL, Collins CA, Manasanch EE, Ramaprasad C, van Besien K. Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide. Lancet Oncol 7(5):436-8, 5/2006. PMID: 16648049.
12. Szekely AM, Bleichert F, Nümann A, Van Komen S, Manasanch EE, Ben Nasr A, Canaan A, Weissman SM. Werner protein protects nonproliferating cells from oxidative DNA damage. Mol Cell Biol 25(23):10492-506, 12/2005. PMCID: PMC1291253.

Invited Articles

1. Roschewski M, Manasanch EE, Wilson WH. Management of heavy chain diseases: the challenges of biologic heterogeneity. Oncology (Williston Park) 28(1):63-5, 1/2014. PMID: 24683720.

Abstracts

1. Bhutani M, Turkbey B, Tan E, Korde N, Kwok M, Manasanch EE, Tageja N, Mailankody S, Roschewski MJ, Mulquin M, Lamping E, Weiss BM, Mena E, Lindenberg L, Calvo KR, Maric I, Choyke PL, Kurdziel KA, Landgren O. Focal bone marrow processes and early bone lesions in patients with multiple myeloma (MM) precursor diseases: A prospective study using molecular imaging. J Clin Oncol 32:5s, 2014 (suppl; abstr 8587) 32(5s) (#8587), 6/2014.
2. Dosani T, Korde N, Manasanch EE, M, Tageja N, Mailankody S, Roschewski MJ, Kwok M, Kazandjian DG, Landgren O, Maric I. Large granular lymphocyte (LGL) subsets in smoldering multiple myeloma (SMM): Immunophenotypic profiles that predict progression to multiple myeloma (MM). J Clin Oncol 32(5s) (#8587), 6/2014.
3. Tageja N, Wang W, Plyler R, Corrigan-Cummins M, Korde N, Manasanch EE. Altered cytokine profiles in multiple myeloma (MM) and precursor disease: Predictors of progression and potential targets for treatment. Journal of Clinical Oncology 31(15) (#8597), 6/2013.
4. Manasanch EE, Korde N, Yuan C et al. Biological variations of plasma cells in the bone marrow of smoldering multiple myeloma (SMM) and multiple myeloma (MM) patients: multiple biopsies in the same patient. Journal of Clinical Oncololgy 31(15) (#e19506), 6/2013.
5. Landgren O, |BManasanch EE. Clinical and Correlative (Phase II) Pilot Study – Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (Dex) in High Risk Smoldering Multiple Myeloma (“Early Myeloma”). Blood 122(21), 2013.
6. Landgren C, Zingone A, Kwok M, Manasanch EE et al. Clinical and correlative pilot study of carfilzomib, lenalidomide and dexamethasone followed by lenalidomide extended dosing (CRD-R) in high risk smoldering multiple myeloma. IMWG Khyoto, Japan, 2013.
7. Korde N, Zingone A, Kwok M, Manasanch EE et al. Combination CRd therapy followed by extended LEN dosing in newly diagnosed MM patients shows deep response rates corroborated by MRD assays and tolerable side effects. EHA #B4823 (#B4823), 2013.
8. Manasanch EE, Fernandez de Larrea C, Zingone A et al. Enzymatic activity of circulating plasma proteasomes (cProt) in newly diagnosed multiple myeloma (NDMM) patients undergoing treatment with carfilzomib, revlimid and dexamethasone (CRd). Blood 122(21), 2013.
9. Mailankody S, Korde N, Faham M, Kwok M, Manasanch EE et al. Molecular sequencing for minimal residual disease (MRD) detection in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone. Blood 122(21), 2013.
10. Bhutani M , Korde N, Kwok M, Manasanch EE et al. Normalization of serum free light chain (sFLC) ratio as a biomarker for negative minimal residual disease (MRD) in patients treated with carfilzomib, lenalidomide and dexamethasone followed by lenalidomide maintenance (CRd-R) for newly diagnosed myeloma. Blood 122(21), 2013.
11. Manasanch EE, Jordan E, Korde N et al. Plasma cell proliferation fraction and the risk of progression from smoldering multiple mieloma (SMM) to multiple mieloma (MM). EHA #B1495 (#B1495), 2013.
12. Fernandez C, Zingone A, Manasanch EE et al. Plasma circulating proteasomes as biomarkers along natural history of asymptomatic monoclonal gammopathies. Blood 122(21), 2013.
13. Korde N, Espana K, Manasanch EE et al. Uninvolved Heavy-light-chain Pair Suppression (UHLCPs) in Smoldering Myeloma: New Insights. IMWG Kyoto, Japan, 2013.
14. Kwok M, Korde N, Manasanch EE et al. Altered plasma cell characteristics in smoldering myeloma and MGUS patients preceding immune-related conditions. Blood 120(21) (#4006), 11/2012.
15. Korde N, Liu QY, Kwok M, Manasanch EE et al. Early myelodysplastic changes present in substantial proportion of monoclonal gammopathy of unknown significance (MGUS) and smoldering multiple myeloma (SMM) patients. Blood 120(21) (#1805), 11/2012.
16. Thembare P, Yuan C, Korde N, Manasanch EE et al. Peripheral blood involvement with minimal disease is common in multiple myeloma but not in smoldering myeloma. Blood 120(21) (#4994), 11/2012.
17. Korde N, Zingone A, Kwok M, Mananasanch EE et al. Phase II clinical and correlative study of carfilzomib, lenalidomide and dexamethasone (CRd) followed by lenalidomide extender dosing (CRD-R) in newly diagnosed multiple myeloma (MM) patients. Blood 120(21) (#732), 11/2012.
18. Korde N, Zingone A, Kwok M, Manasanch EE. et a;. Phase II clinical and correlative study of carfilzomib, lenalidomide and dexamethasone (CRd) in newly diagnosed multiple myeloma (MM) patients. Blood 120(21) (#732), 11/2012.
19. Cherry BM, Korde N, Kwok M, Manasanch EE et al. A prospective clinical study evaluating current models for risk of progression from smoldering multiple myeloma (SMM) to multiple myeloma (MM). Journal of Clinical Oncology 30(15) (#8088), 5/2012.
20. Korde N, Zingone A, Kwok M, Manasanch EE et al. Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone (CRd) in newly diagnosed multiple myeloma (MM) patients. Jounal of Clinical Oncology 30(15) (#e18568), 5/2012.
21. Kwok M, Korde N, Manasanch EE et al. Role of immune-related conditions in smoldering myeloma and MGUS. Journal of Clinical Oncology 30(15) (#8104), 5/2012.
22. Manasanch EE, Wilkerson J, Xiu L et al. Assessment of Tumor Growth (g) and Regression (d) Rate Constants in Patients with Multiple Myeloma (MM) Shows That the Superiority of Bortezomib with Liposomal Doxorubicin (PLD+B) Over Bortezomib Alone (B) Is a Result of Reduced Growth of Refractory Tumor Cells and Not of Higher Regression Rates, and Provides An Earlier Efficacy Endpoint That Allows for Comparison Across Trials. Blood 118(21) (#5113), 11/2011.
23. Manasanch EE, Mcdade TP, Bodnari A, et al. Tumor registry versus physician medical record review: a head-to-head comparison of malignant pancreatic neuroendocrine tumor (mPNET) cases. Journal of Clinical Oncology 27(15s) (#suppl abstr 6600), 2009.

Book Chapters

1. Manasanch EE, Tageja N, Landgren O. Multiple Myeloma. In: Bethesda Handbook of Clinical Hematology, 2013.
2. Manasanch EE, Lozier J. Venous Thromboembolism. In: Bethesda Handbook of Clinical Hematology, 2013.

Letters to the Editor

1. Manasanch EE, Braylan R, Stetler-Stevenson M, Yuan C, Gounden V, Korde N, Tageja N, Bhutani M, Calvo K, Maric I, Roschewski M, Staudt LM, Landgren O. Lack of MYD88 L265P in non-immunoglobulin M lymphoplasmacytic lymphoma. Leuk Lymphoma. e-Pub 12/2013. PMID: 23915224.
2. Manasanch EE, Freeman AF, Pittaluga S, Costello R, Holland SM, Landgren O. Serum free light chains as predictors of lymphomagenesis in patients with autosomal dominant hyper-immunoglobulin E syndrome (Job's syndrome). Leuk Lymphoma 54(6):1316-7, 6/2013. e-Pub 11/2012. PMID: 23039380.

Last updated: 7/25/2014